FIALA, O., M. PESEK, J. FINEK, J. KREJCI, L. HAVEL, M. HRNCIARIK, F. SALAJKA, Zbyněk BORTLÍČEK, L. BENESOVA and M. MINARIK. Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma. Bratislava: Slovenská akademie vied, 2013, vol. 60, No 6, p. 676-682. ISSN 0028-2685. doi:10.4149/neo_2013_086.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Erlotinib in the treatment of advanced squamous cell NSCLC
Authors FIALA, O. (203 Czech Republic), M. PESEK (203 Czech Republic), J. FINEK (203 Czech Republic), J. KREJCI (203 Czech Republic), L. HAVEL (203 Czech Republic), M. HRNCIARIK (203 Czech Republic), F. SALAJKA (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution), L. BENESOVA (203 Czech Republic) and M. MINARIK (203 Czech Republic).
Edition Neoplasma, Bratislava, Slovenská akademie vied, 2013, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.642
RIV identification code RIV/00216224:14110/13:00069219
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4149/neo_2013_086
UT WoS 000325039800011
Keywords in English squamous cell; NSCLC; erlotinib; targeted treatment; EGFR-TKI
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 29. 4. 2014 13:29.
Abstract
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib’s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage(IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001). The most common adverse effects were rash and diarrhoea. In conclusion erlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC.
PrintDisplayed: 26. 6. 2022 09:53